PT1538202E - Produção de alga-galactosidase a humana - Google Patents

Produção de alga-galactosidase a humana Download PDF

Info

Publication number
PT1538202E
PT1538202E PT40301079T PT04030107T PT1538202E PT 1538202 E PT1538202 E PT 1538202E PT 40301079 T PT40301079 T PT 40301079T PT 04030107 T PT04030107 T PT 04030107T PT 1538202 E PT1538202 E PT 1538202E
Authority
PT
Portugal
Prior art keywords
galactosidase
production
human alpha
sample
gal
Prior art date
Application number
PT40301079T
Other languages
English (en)
Inventor
Douglas A Treco
Richard F Selden
Melanie D Williams
Marianne Borowski
Frances P Gillespie
Carol M Kinoshita
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Publication of PT1538202E publication Critical patent/PT1538202E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
PT40301079T 1996-09-13 1997-09-12 Produção de alga-galactosidase a humana PT1538202E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71261496A 1996-09-13 1996-09-13

Publications (1)

Publication Number Publication Date
PT1538202E true PT1538202E (pt) 2014-04-22

Family

ID=24862863

Family Applications (1)

Application Number Title Priority Date Filing Date
PT40301079T PT1538202E (pt) 1996-09-13 1997-09-12 Produção de alga-galactosidase a humana

Country Status (21)

Country Link
EP (4) EP0935651B1 (pt)
JP (7) JP4001925B2 (pt)
KR (2) KR20050084473A (pt)
CN (1) CN1268741C (pt)
AT (1) ATE286120T1 (pt)
AU (1) AU4424497A (pt)
CA (1) CA2265464C (pt)
DE (1) DE69732129T2 (pt)
DK (2) DK2374876T3 (pt)
ES (3) ES2458292T3 (pt)
HK (3) HK1022173A1 (pt)
HU (2) HU227189B1 (pt)
IL (2) IL128960A (pt)
MX (1) MX340738B (pt)
NO (4) NO328443B1 (pt)
NZ (2) NZ506214A (pt)
PL (1) PL190041B1 (pt)
PT (1) PT1538202E (pt)
RU (1) RU2179034C2 (pt)
TW (1) TW585919B (pt)
WO (1) WO1998011206A2 (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458574B1 (en) * 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US6083725A (en) 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
IL135578A0 (en) * 1997-10-29 2001-05-20 Genzyme Corp Compositions and methods for treating lysosomal storage disease
EP1658857A1 (en) * 1997-10-29 2006-05-24 Genzyme Corporation Compositions and methods for treating lysosomal storage disease
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
AU2016250357B2 (en) * 1999-03-11 2018-11-01 Shire Human Genetic Therapies, Inc. Treatment of alpha-Galactosidase A deficiency
AU2004242550B2 (en) * 1999-03-11 2008-04-03 Shire Human Genetic Therapies, Inc. Treatment of alpha-Galactosidase A deficiency
AU2012241170B2 (en) * 1999-03-11 2016-07-28 Shire Human Genetic Therapies, Inc. Treatment of alpha-Galactosidase A deficiency
EP2275559A3 (en) * 1999-09-28 2011-03-23 Shire Human Genetic Therapies, Inc. Optimized messenger RNA
WO2002064799A2 (en) 1999-09-28 2002-08-22 Transkaryotic Therapies, Inc. Optimized messenger rna
AU1647501A (en) 1999-12-10 2001-06-18 Cytos Biotechnology Ag Replicon based activation of endogenous genes
BR0108077A (pt) 2000-02-04 2002-10-22 Children S Hospital Res Founda Processo para reduzir placas ateroscleróticas em um mamìfero, método para tratamento da aterosclerose em um mamìfero, composição, métodos para prover proteìna ou polipeptìdeo hidrolisante de lipìdeo biologicamente ativo ou mistura deles, para células de um mamìfero tendo deficiência na proteìna ou polipeptìdeo hidrolisante de lipìdeo biologicamente ativo , para prover lipase de ácido lisossomal biologicamente ativa para células de um mamìfero tendo deficiência de lipase de ácido lisossomal biologicamente ativa, para prover lipase de ácido lisossoal biologicamente ativa para células de um mamìfero com aterosclerose, para tratamento da doença de wolman em um mamìfero, para tratamento de doença de armazenagem de colesteril éster em um mamìfero, e, para tratamento da aterosclerose em um mamìfero
WO2001097829A2 (en) 2000-06-19 2001-12-27 Genzyme Corporation Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US7138262B1 (en) * 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
IL140110A0 (en) * 2000-12-05 2002-02-10 Applied Research Systems Improvement of homogeneity and secretion of recombinant proteins in mammalian systems
NZ536361A (en) 2002-04-25 2008-05-30 Shire Human Genetic Therapies Treatment of alpha-galactosidase a deficiency
ATE521701T1 (de) 2003-01-22 2011-09-15 Univ Duke Verbesserte konstrukte zur expression lysosomaler polypeptide
WO2007058381A1 (ja) * 2005-11-18 2007-05-24 Tokyo Metropolitan Organization For Medical Research 基質特異性を変換した新規高機能酵素
AR059089A1 (es) 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
ES2391657T3 (es) 2006-02-07 2012-11-28 Shire Human Genetic Therapies, Inc. Composiciones estabilizadas de proteínas que tienen un resto tiol libre
JP2009526066A (ja) 2006-02-09 2009-07-16 ジェンザイム・コーポレーション 遅速性脳室内送達
US8569032B2 (en) 2007-05-18 2013-10-29 Tokyo Metropolitan Institute Of Medical Science Proteins having acquired A-galactosidase activity
SI2889043T1 (sl) 2008-12-16 2019-08-30 Genzyme Corporation Sintetične vmesne spojine za pripravo konjugatov oligosaharid-protein
RU2733466C2 (ru) 2009-07-28 2020-10-01 Шайр Хьюман Дженетик Терапиз Композиции и способы для лечения болезни гоше
MX338426B (es) 2010-04-23 2016-04-15 Synageva Biopharma Corp Enzima de enfermedad del almacenamiento lisosomico.
US9453847B2 (en) 2010-07-19 2016-09-27 Shire Human Genetic Therapies, Inc. Mannose receptor C type 1 (MRC1) codon optimized cell line and uses thereof
EP2613798B2 (en) 2010-09-09 2018-01-24 Synageva BioPharma Corp. Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients
WO2012112681A1 (en) 2011-02-15 2012-08-23 Shire Human Genetic Therapies, Inc. Methods for treating lysosomal acid lipase deficiency
KR20140091721A (ko) * 2011-11-02 2014-07-22 제넨테크, 인크. 오버로드 및 용리 크로마토그래피
KR20140138850A (ko) 2012-03-02 2014-12-04 샤이어 휴먼 지네틱 테라피즈 인크. Ｉｉｉ형 고셔병을 치료하기 위한 조성물 및 방법
CN104507503A (zh) * 2012-06-29 2015-04-08 康斯乔最高科学研究公司(Csic) 用于递送生物活性化合物的功能化脂质体
WO2014016873A1 (en) * 2012-07-26 2014-01-30 Jcr Pharmaceuticals Co., Ltd. Method for production of recombinant human alpha-galactosidase a
JP6226435B2 (ja) * 2012-07-26 2017-11-08 Ｊｃｒファーマ株式会社 組換えヒトα−ガラクトシダーゼＡの製造方法
CN111172135A (zh) 2012-10-24 2020-05-19 建新公司 使用mes和mops作为流动相改性剂从多峰树脂洗脱生物分子
TW202332774A (zh) * 2013-10-23 2023-08-16 美商健臻公司 重組醣蛋白及其用途
BR112017013300A2 (pt) * 2014-12-22 2018-02-27 Codexis Inc alfa galactosidase a recombinante e/ou fragmento de alfa galactosidase a recombinante biologicamente ativo, composição, sequência de polinucleotídeos recombinantes, vetor de expressão, célula hospedeira, métodos para produzir uma variante de alfa galactosidase a e para tratar e/ou prevenir os sintomas da doença de fabry, composição farmacêutica, e, uso das composições.
WO2016116966A1 (en) 2015-01-22 2016-07-28 Jcr Pharmaceuticals Co., Ltd. Method for purification of recombinant human alpha-galactosidase a from material containing contaminant host cell proteins
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
EP3646899A4 (en) 2017-06-30 2020-07-08 FUJIFILM Corporation TREATMENT AGENT FOR LYSOSOMAL DISEASE
ES2716305B2 (es) 2017-12-11 2019-11-27 Fund Biomedica Galicia Sur Uso de chaperonas farmacologicas para el tratamiento de enfermedades de deposito lisosomal
BR112021011750A2 (pt) 2018-12-20 2021-08-31 Codexis, Inc. Alfa-galactosidase a recombinante e/ou fragmento de alfa-galactosidase a recombinante, composição, sequência de polinucleotídeo recombinante, vetor de expressão, célula hospedeira, métodos para produzir uma variante de alfa-galactosidase a e para tratar e/ou prevenir os sintomas da doença de fabry, composição farmacêutica, e, uso das composições
CN111308095A (zh) * 2020-03-04 2020-06-19 北京师范大学 用于诊断前列腺癌的尿液蛋白标记物
WO2024044697A2 (en) * 2022-08-24 2024-02-29 Walking Fish Therapeutics, Inc. Compositions and methods for treatment of fabry disease

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2619719B1 (fr) * 1987-09-01 1991-05-10 Sanofi Sa Procede d'obtention d'interleukine-2 a partir de cellules eucaryotes, vecteurs necessaires a sa mise en oeuvre et lignees cellulaires hautement productrices
FI96121C (fi) * 1987-10-02 1996-05-10 Zymogenetics Inc DNA-rakenne ja menetelmä heterologisen proteiinin tuottamiseksi
WO1990011353A1 (en) * 1989-03-24 1990-10-04 Research Corporation Technologies, Inc. Recombinant alpha-galactosidase, a therapy for fabry disease
US5179023A (en) 1989-03-24 1993-01-12 Research Corporation Technologies, Inc. Recombinant α-galactosidase a therapy for Fabry disease
NZ234453A (en) * 1989-07-13 1993-01-27 Sanofi Sa Recombinant dna encoding urate oxidase, and vector, host, protein and pharmaceutical compositions associated therewith
IL95330A0 (en) * 1989-08-11 1991-06-30 Lilly Co Eli Expression of a functional insect specific toxin gene in mammalian cells
EP0550675A1 (en) * 1990-09-28 1993-07-14 Cephalon, Inc. Transgenic animals with alzheimer's amyloid precursor gene
US5401650A (en) * 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
US5356804A (en) 1990-10-24 1994-10-18 Mount Sinai School Of Medicine Of The City Of New York Cloning and expression of biologically active human α-galactosidase A
WO1993008292A1 (en) * 1991-10-16 1993-04-29 Agracetus, Inc. Particle-mediated transformation of animal somatic cells
PT101031B (pt) * 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
SE9300105D0 (sv) * 1993-01-15 1993-01-15 Kabi Pharmacia Ab Stable protein solution
ATE229980T1 (de) * 1993-07-02 2003-01-15 Incyte Pharma Inc Glycosilierte und nichtglycolisierte bakterizide/die permeabilität erhoehende proteine und methoden zu ihrer herstellung
ATE275194T1 (de) 1994-01-13 2004-09-15 Rogosin Inst Makroeingekapselte sekretorische zellen
JP2984552B2 (ja) * 1994-09-02 1999-11-29 大和化成株式会社 ラッカーゼおよびその生産方法
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
JPH08196293A (ja) * 1995-01-25 1996-08-06 Mitsui Toatsu Chem Inc タンパク質の製造方法
CN1161468C (zh) * 1995-02-15 2004-08-11 安姆根有限公司 Mpl配体类似物

Also Published As

Publication number Publication date
DK2374876T3 (en) 2016-05-30
MX340738B (es) 2016-07-22
JP2009102321A (ja) 2009-05-14
CN1230220A (zh) 1999-09-29
EP1538202A2 (en) 2005-06-08
JP4001925B2 (ja) 2007-10-31
CA2265464A1 (en) 1998-03-19
RU2179034C2 (ru) 2002-02-10
HU227189B1 (en) 2010-10-28
JP4313381B2 (ja) 2009-08-12
NZ334721A (en) 2001-01-26
PL332188A1 (en) 1999-08-30
EP1538202A3 (en) 2007-05-30
DE69732129D1 (de) 2005-02-03
NO20141168L (no) 1999-05-10
JP2001504324A (ja) 2001-04-03
HK1022173A1 (en) 2000-07-28
ES2581828T3 (es) 2016-09-07
CN1268741C (zh) 2006-08-09
WO1998011206A2 (en) 1998-03-19
NO340408B1 (no) 2017-04-18
ES2234032T3 (es) 2005-06-16
NO330687B1 (no) 2011-06-06
HK1074058A1 (en) 2005-10-28
IL128960A (en) 2007-10-31
IL184637A0 (en) 2009-09-22
JP2007000145A (ja) 2007-01-11
HU1000445D0 (en) 2010-11-29
HK1162580A1 (zh) 2012-08-31
EP0935651A2 (en) 1999-08-18
NO328443B1 (no) 2010-02-22
CA2265464C (en) 2007-06-26
AU4424497A (en) 1998-04-02
NO991225D0 (no) 1999-03-12
EP1538202B1 (en) 2014-01-22
HUP9904666A3 (en) 2001-09-28
IL128960A0 (en) 2000-02-17
EP2374876A3 (en) 2012-10-24
EP2374876A2 (en) 2011-10-12
JP2015044830A (ja) 2015-03-12
ATE286120T1 (de) 2005-01-15
NO991225L (no) 1999-05-10
JP2007289201A (ja) 2007-11-08
KR100547402B1 (ko) 2006-02-01
KR20050084473A (ko) 2005-08-26
JP2012019793A (ja) 2012-02-02
EP2327775A2 (en) 2011-06-01
KR20000036078A (ko) 2000-06-26
JP2009060918A (ja) 2009-03-26
WO1998011206A3 (en) 1998-08-13
PL190041B1 (pl) 2005-10-31
HU230275B1 (hu) 2015-11-30
HU9904666A (en) 2000-05-28
JP4313405B2 (ja) 2009-08-12
TW585919B (en) 2004-05-01
ES2458292T3 (es) 2014-04-30
EP2327775A3 (en) 2012-10-24
DE69732129T2 (de) 2005-12-08
DK1538202T3 (en) 2014-03-24
EP2374876B1 (en) 2016-04-13
EP0935651B1 (en) 2004-12-29
JP5590788B2 (ja) 2014-09-17
NO20110496L (no) 1999-05-10
IL184637A (en) 2015-07-30
NO20090583L (no) 1999-05-10
NZ506214A (en) 2002-11-26

Similar Documents

Publication Publication Date Title
PT1538202E (pt) Produção de alga-galactosidase a humana
ZA966507B (en) Process for the production of epoxides from olefins.
HU9603503D0 (en) Process for producing olefins
EP0751105A3 (de) Verfahren zur Oxidation organischer Verbindungen
HU9602820D0 (en) Process for decomposing of cycloalkyl hydroperoxide
IL147575A0 (en) Method for purifying keratinocyte growth factors
EP0603671A3 (de) Verfahren zur Reaktivierung von gereinigten Membranproteinen.
IL128028A0 (en) Treatment of psychotic disorders
EP0604092A3 (en) Improved process for the production of alkyl halosilanes.
EP0682034A3 (en) Process for the preparation of cyanoalkylorganooxysilanes from cyanoalkylchlorosilanes.
WO1997035015A3 (de) Tyrosin-phosphatase-verwandtes protein
GR3005080T3 (pt)
AU4106396A (en) Process for performing retro-aldol reaction
MX9604599A (es) Procedimiento para la sintesis enzimatica de nucleotido-6-desoxi-d-xilo-4-hexulosas.
EP0795542A4 (en) PROCESS FOR PRODUCING ACRYLONITRILE DIMERS
EP0630970A3 (en) Process for the preparation of canthaxanthin.
SI0813597T1 (sl) Postopek za ciscenje od vitamina K odvisnih koagulacijskih faktorjev s kromatografijo
HU913531D0 (en) Process for the production of leather treating substance from environment-damaging, protein containing sewage
IL112698A (en) Displacement chromatography process for purification of hemoglobin
WO1998056822A3 (en) Process for the separation of specific immunoglobulins from standard plasma
ZA967336B (en) Process for the recovery of gold
FI963244A (fi) Menetelmä 2-butyyli-2-etyyli-1,3-propaanidiolin erottamiseksi sitä sisältävistä reaktioseoksista